



(19) Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number: 0 508 798 A1

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: 92303193.4

(51) Int. Cl.<sup>5</sup>: C07D 243/24, A61K 31/55

(22) Date of filing: 09.04.92

(30) Priority: 10.04.91 US 683407  
20.12.91 US 812876  
10.03.92 US 848789

(43) Date of publication of application:  
14.10.92 Bulletin 92/42

(84) Designated Contracting States:  
CH DE FR GB IT LI NL


(71) Applicant: MERCK & CO. INC.  
126, East Lincoln Avenue P.O. Box 2000  
Rahway New Jersey 07065-0900 (US)

(72) Inventor: Bock, Mark G.  
1603 Leon Drive  
Hatfield, PA 19440 (US)  
Inventor: Freidinger, Roger M.  
744 Newport Lane  
Lansdale, PA 19446 (US)

(74) Representative: Thompson, John Dr. et al  
Merck & Co., Inc. European Patent  
Department Terlings Park Eastwick Road  
Harlow, Essex CM20 2QR (GB)

(54) Cholecystokinin antagonists.

(57) Benzodiazepine analogs of the formula:



are disclosed which are antagonists of gastrin and cholecystokinin (CCK).

EP 0 508 798 A1

FIELD OF THE INVENTION

This invention relates to the discovery of Benzodiazepine analogs of Formula I for use as antagonists of cholecystokinin (CCK) and gastrin when administered to animals, preferably humans.

5

BACKGROUND OF THE INVENTION

The Benzodiazepine analogs of Formula I of this invention are useful in treating various diseases caused by an excess of CCK or gastrin. Cholecystokinins (CCK) and gastrin are structurally related neuropeptides which exist in gastrointestinal tissue and in the central nervous system (see, V. Mutt, Gastrointestinal Hormones, G.B.J. Glass, Ed., Raven Press, N.Y., p. 169 and G. Nission, ibid. p. 127).

Cholecystokinins include CCK-33, a neuropeptide of thirty-three amino acids in its originally isolated form (see, Mutt and Jorpes, Biochem. J. 125, 678 (1971)), its carboxyl terminal octapeptide, CCK-8 (also a naturally-occurring neuropeptide and the minimum fully active sequence), and 39- and 12-amino acid forms. Gastrin occurs in 34-, 17- and 14-amino acid forms, with the minimum active sequence being the C-terminal tetrapeptide, Trp-Met-Asp-Phe-NH<sub>2</sub>, which is the common structural element shared by both CCK and gastrin.

CCK's are believed to be physiological satiety hormones, thereby possibly playing an important role in appetite regulation (G. P. Smith, Eating and Its Disorders, A. J. Stunkard and E. Stellar, Eds, Raven Press, New York, 1984, p. 67), as well as also stimulating colonic motility, gall bladder contraction, pancreatic enzyme secretion, and inhibiting gastric emptying. They reportedly co-exist with dopamine in certain mid-brain neurons and thus may also play a role in the functioning of dopaminergic systems in the brain, in addition to serving as neurotransmitters in their own right (see: A. J. Prange et al., "Peptides in the Central Nervous System", Ann. Repts. Med. Chem. 17, 31, 33 [1982] and references cited therein; J. A. Williams, Biomed. Res. 3 107 [1982]; and J. E. Morley, Life Sci. 30, 479, [1982]).

25 The primary role of gastrin, on the other hand, appears to be stimulation of the secretion of water and electrolytes in the stomach, and, as such, it is involved in control of gastric acid and pepsin secretion. Other physiological effects of gastrin then include increased mucosal blood flow and increased antral motility. Rat studies have shown that gastrin has a positive trophic effect on the gastric mucosa, as evidenced by increased DNA, RNA and protein synthesis. See e.g. U.S. Serial No. 452,023, corresponding to EP-A-0434364.

30 Antagonists to CCK and to gastrin have been useful for preventing and treating CCK-related and/or gastrin-related disorders of the gastrointestinal (GI) and central nervous (CNS) systems of animals, preferably mammals, and especially those of humans. Just as there is some overlap in the biological activities of CCK and gastrin, antagonists also tend to have affinity for both receptors. In a practical sense, however, there is enough selectivity for the different receptors that greater activity against specific CCK- or gastrin-related disorders can often also be identified.

35 Selective CCK antagonists are themselves useful in treating CCK-related disorders of the appetite regulatory systems of animals as well as in potentiating and prolonging opiate-mediated analgesia, thus having utility in the treatment of pain [see P. L. Faris et al., Science 226, 1215 (1984)]. Selective gastrin antagonists are useful in the modulation of CNS behavior, as a palliative for gastrointestinal neoplasms, and in the treatment 40 and prevention of gastrin-related disorders of the gastrointestinal system in humans and animals, such as peptic ulcers, Zollinger-Ellison syndrome, antral G cell hyperplasia and other conditions in which reduced gastrin activity is of therapeutic value. See e.g. U.S. Patent 4,820,834. It is further expected that the CCK antagonists of Formula I are useful anxiolytic agents particularly in the treatment of panic and anxiety disorders.

45 Since CCK and gastrin also have trophic effects on certain tumors [K. Okyama, Hokkaido J. Med. Sci., 60, 206-216 (1985)], antagonists of CCK and gastrin are useful in treating these tumors [see, R.D. Beauchamp et al., Ann. Surg., 202, 303 (1985)].

50 Distinct chemical classes of CCK-receptor antagonists have been reported [R. Freidinger, Med. Res. Rev. 9, 271 (1989)]. The first class comprises derivatives of cyclic nucleotides, of which dibutyryl cyclic GMP has been shown to be the most potent by detailed structure-function studies (see, N. Barlas et al., Am. J. Physiol., 242, G 161 (1982) and P. Robberecht et al., Mol. Pharmacol., 17, 268 (1980)).

55 The second class comprises peptide antagonists which are C-terminal fragments and analogs of CCK, of which both shorter (Boc-Met-Asp-Phe-NH<sub>2</sub>, Met-Asp-Phe-NH<sub>2</sub>), and longer (Cbz-Tyr(SO<sub>3</sub>H)-Met-Cly-Trp-Met-Asp-NH<sub>2</sub>) C-terminal fragments of CCK can function as CCK antagonists, according to recent structure-function studies (see, R. T. Jensen et al., Biochem. Biophys. Acta., 757, 250 (1983), and M. Spanarkel et al., J. Biol. Chem., 258, 6746 (1983)). The latter compound was recently reported to be a partial agonist [see, J. M. Howard et al., Gastroenterology 86 (5) Part 2, 1118 (1984)].

The third class of CCK-receptor antagonists comprises the amino acid derivatives: proglumide, a derivative of glutamic acid, and the N-acyl tryptophans including para-chlorobenzoyl-L-tryptophan (benzotript), [see,

W. F. Hahne et al., Proc. Natl. Acad. Sci. U.S.A., 78, 6304 (1981), R. T. Jensen et al., Biochem. Biophys. Acta., 761, 269 (1983)]. All of these compounds, however, are relatively weak antagonists of CCK ( $IC_{50}$ : generally  $10^{-4}$ M[although more potent analogs of proglumide have been recently reported in F. Makovec et al., Arzneim-Forsch Drug Res., 35 (ii), 1048 (1985) and in German Patent Application DE 3522506A1], but down to  $10^{-6}$ M in the case of peptides), and the peptide CCK-antagonists have substantial stability and absorption problems.

In addition, a fourth class consists of improved CCK-antagonists comprising a nonpeptide of novel structure from fermentation sources [R. S. L. Chang et al., Science, 230, 177-179 (1985)] and 3-substituted benzodiazepines based on this structure [published European Patent Applications 167 919, 167 920 and 169 392, B. E. Evans et al., Proc. Natl. Acad. Sci. U.S.A., 83, P. 4918-4922 (1986) and R.S.L. Chang et al, ibid, p. 4923-4926] have also been reported.


No really effective receptor antagonists of the *in vivo* effects of gastrin have been reported (J. S. Morley, Gut Pept. Ulcer Proc., Hiroshima Symp. 2nd, 1983, p. 1), and very weak *in vitro* antagonists, such as proglumide and certain peptides have been described [(J. Martinez, J. Med. Chem. 27, 1597 (1984)]. Recently, however, pseudopeptide analogs of tetragastrin have been reported to be more effective gastrin antagonists than previous agents [J. Martinez et al., J. Med. Chem., 28, 1874-1879 (1985)].

A new class of Benzodiazepine antagonist compounds has further been reported which binds selectively to brain CCK (CCK-B) and gastrin receptors [see M. Bock et al., J. Med. Chem., 32, 13-16 (1989)]. One compound of interest reported in this reference to be a potent and selective antagonist of CCK-B receptors is (R)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N<sup>1</sup>-(3-methylphenyl) urea (See U.S. Patent 4,820,834.) One disadvantage of the new CCK-B compound reported in Bock et al., J. Med. Chem., 32, 13-16 (1989) and U.S. Patent 4,820,834, is that these CCK-B compounds are poorly water soluble.

It is, therefore, an object of the present invention to provide antagonists of CCK and gastrin. If an antagonist compound could be prepared which would bind with the cell surface receptor of CCK or gastrin, then the antagonist compounds of this invention could be used to block the effect of CCK and gastrin. Another object of the present invention is to provide novel CCK and gastrin antagonist compounds which are water soluble. Other objects of the present invention are to provide methods of inhibiting the action of CCK and gastrin through the administration of novel benzodiazepine analog compounds. The above and other object are accomplished by the present invention in the manner more fully described below.

### 30 SUMMARY OF THE INVENTION

The present invention provides Benzodiazepine analogs of the formula:




for use as antagonists of CCK and gastrin. The above-mentioned compounds can be used in a method of acting upon a CCK and/or gastrin receptor which comprises administering a therapeutically effective but non-toxic amount of such compound to an animal, preferably a human. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, dispersed therein, an effective but non-toxic amount of such compound is another aspect of this invention.


### DETAILED DESCRIPTION OF THE INVENTION

55 Benzodiazepine analogs of Formula I provide antagonists of CCK and gastrin. The present invention further provides novel CCK and gastrin antagonist compound which are water soluble. The Benzodiazepine analogs of Formula I are useful in a method of antagonizing the binding of CCK to CCK receptors or antagonizing the


binding of gastrin to gastrin receptors. The novel Benzodiazepine analogs of the present invention are illustrated by compounds having the formula:



wherein  
R<sup>1</sup> is H, - (CH<sub>2</sub>)<sub>2</sub>-CO<sub>2</sub>CH<sub>3</sub>, or  
-(CH<sub>2</sub>)<sub>2</sub>-CO<sub>2</sub>H;



R<sup>3</sup> is absent, one or two of Halogen or CH<sub>3</sub>;  
R<sup>4</sup> is absent, one or two of Halogen or CH<sub>3</sub>;  
R<sup>5</sup> is



or the optical isomers, prodrugs or pharmaceutically acceptable salts thereof.

40 Preferred compounds of this invention as set forth in the Examples are:  
N-{1,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl}-N'-carboxyethyl-N'-[3-methylphenyl]-urea}; and  
N-{1,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl}-N-carboxyethyl-N'-[3-methylphenyl]-urea}.

45 It will be appreciated that formula (I) is intended to embrace all possible isomers, including optical isomers, and mixtures thereof, including racemates.

The present invention includes within its scope prodrugs of the compounds of formula I above. In general, such prodrugs will be functional derivatives of the compounds of formula I which are readily convertible in vivo into the required compound of formula I. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bungaard, Elsevier, 1985.

50 The pharmaceutically acceptable salts of the compounds of Formula I include the conventional non-toxic salts or the quarternary ammonium salts of the compounds of Formula I formed, e.g., from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from 55 organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

The pharmaceutically acceptable salts of the present invention can be synthesized from the compounds

of Formula I which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.

The pharmaceutically acceptable salts of the acids of Formula I are also readily prepared by conventional procedures such as treating an acid of Formula I with an appropriate amount of a base, such as an alkali or alkaline earth metal hydroxide e.g. sodium, potassium, lithium, calcium, or magnesium, or an organic base such as an amine, e.g., dibenzylethylenediamine, trimethylamine, piperidine, pyrrolidine, benzylamine and the like, or a quaternary ammonium hydroxide such as tetramethylammonium hydroxide and the like.

The compounds of Formula I antagonize CCK and/or gastrin and are useful as pharmaceutical agents for animals, preferably for mammals, and most especially for humans, for the treatment and prevention of gastro-intestinal disorders and central nervous system disorders.

Examples of such gastrointestinal disorders include ulcers, such as peptic and gastrointestinal ulcers, irritable bowel syndrome, gastroesophageal reflux disease or excess pancreatic or gastrin secretion, acute pancreatitis, or motility disorders, Zollinger-Ellison syndrome, and antral and cell hyperplasia.

Examples of central nervous system disorders include central nervous system disorders caused by CCK interaction with dopamine, such as neuroleptic induced tardive dyskinesia, Parkinson's disease, schizophrenia, other psychosis or Gilles de la Tourette syndrome, and disorders of appetite regulatory systems.

The compounds of Formula I may further be useful in the treatment or prevention of additional central nervous system disorders including neurological and psychiatric disorders. Examples of such central nervous system disorders include anxiety disorders and panic disorders, wherein CCK and/or gastrin is involved. Additional examples of central nervous system disorders include panic syndrome, anticipatory anxiety, phobic anxiety, panic anxiety, chronic anxiety, and endogenous anxiety.

The compounds of Formula I may further be useful in the treatment of oncologic disorders wherein CCK or gastrin may be involved. Examples of such oncologic disorders include small cell adenocarcinomas and primary tumors of the central nervous system glial and neuronal cells. Examples of such adenocarcinomas and tumors include, but are not limited to, tumors of the lower esophagus, stomach, intestine, colon and lung, including small cell lung carcinoma.

The compounds of Formula I may further be used to control pupil constriction in the eye. The compounds may be used for therapeutic purposes during eye examinations and intraocular surgery in order to prevent miosis. The compounds may further be used to inhibit miosis occurring in association with iritis, uveitis and trauma.

The compounds of Formula I are also useful for directly inducing analgesia, opiate or non-opiate mediated, as well as anesthesia or loss of the sensation of pain.

The compounds of Formula I may further be useful for preventing or treating the withdrawal response produced by chronic treatment or abuse of drugs or alcohol. Such drugs include, but are not limited to cocaine, alcohol or nicotine.

The compounds of formula (I) may also be useful as neuroprotective agents, for example, in the treatment and/or prevention of neurodegenerative disorders arising as a consequence of such pathological conditions as stroke, hypoglycaemia, cerebral palsy, transient cerebral ischaemic attack, cerebral ischaemia during cardiac pulmonary surgery or cardiac arrest, perinatal asphyxia, epilepsy, Huntington's chorea, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Parkinson's disease, Olivo-pontocerebellar atrophy, anoxia such as from drowning, spinal cord and head injury, and poisoning by neurotoxins, including environmental neurotoxins.

The present invention also encompasses a pharmaceutical composition useful in the treatment of CCK and/or gastrin disorders comprising the administration of a therapeutically effective but non-toxic amount of the compounds of Formula I, with or without pharmaceutically acceptable carriers or diluents.

The compounds of Formula I, may be administered to animals, preferably to mammals, and most especially to a human subject either alone or, preferably, in combination with pharmaceutically-acceptable carriers or diluents, optionally with known adjuvants, such as alum, in a pharmaceutical composition, according to standard pharmaceutical practice. The compounds can be administered orally or parenterally, including intravenous, intramuscular, intraperitoneal, subcutaneous and topical administration.

For oral use of an antagonist of CCK, according to this invention, the selected compounds may be administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch, and lubricating agents, such as magnesium stearate, are commonly added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents may be added. For intramuscular, intraperitoneal, subcutaneous and intravenous use, sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled in order to render the preparation

isotonic.

When a compound according to Formula I is used as an antagonist of CCK or gastrin in a human subject, the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms. However, in most instances, an effective daily dosage will be in the range of from about 0.005 mg/kg to about 50 mg/kg of body weight, and preferably, of from about 0.05 mg/kg to about 50 mg/kg of body weight, and most preferably, of from about 0.5 mg/kg to about 20 mg/kg of body weight administered in single or divided doses.

In some cases, however, it may be necessary to use dosage levels outside these limits. For example, doses as low as about 1 ng/kg, about 0.005 µg to about 0.05 µg, or about 100 ng to about 100 µg/kg may be administered.

In the effective treatment of panic syndrome, panic disorder, anxiety disorder and the like, preferably about 0.05 mg/kg to about 1.0 mg/kg of CCK antagonist maybe administered orally (p.o.), administered in single or divided doses per day (b.i.d.). Other routes of administration are also suitable.

For directly inducing analgesia, anesthesia or loss of pain sensation, the effective dosage range is preferably from about 100 ng/kg to about 1 mg/kg by intraperitoneal administration. Oral administration is an alternative route, as well as others.

In the treatment of irritable bowel syndrome, preferably about 0.1 to 10 mg/kg of CCK antagonist is administered orally (p.o.), administered in single or divided doses per day (b.i.d.). Other routes of administration are also suitable.

The use of a gastrin antagonist as a tumor palliative for gastrointestinal neoplasia with gastrin receptors, as a modulator of central nervous activity, treatment of Zollinger - Ellison snydrome, or in the treatment of peptic ulcer disease, an effective dosage is preferably from about 0.1 to about 10 mg/kg administered one-to-four times daily is indicated.

Because these compounds antagonize the function of CCK in animals, they may also be used as feed additives to increase the food intake of animals in daily dosage preferably from about 0.05 mg/kg to about 50 mg/kg of body weight.

The compounds of Formula I may be prepared according to the reaction schemes as set forth below.

30

35

40



45

50


55

SCHEME 1


5



20

 $\xrightarrow{\text{LiOH, DME, H}_2\text{O}}$ 

40



55

SCHEME 2

5

10

15


20

25

30

35

40

1. CCK Receptor Binding (Pancreas)

45 CCK-8 sulphated was radiolabelled with <sup>125</sup>I-Bolton Hunter reagent (2000 Ci/mmol). Receptor binding was performed according to Chang and Lotti (Proc. Natl. Acad. Sci. 83, 4923-4926, 1986) with minor modifications.

Male Sprague-Dawley rats (150-200g) were sacrificed by decapitation. The whole pancreas was dissected free of fat tissue and was homogenized in 25 volumes of ice-cold 10 mM Hepes buffer with 0.1% soya bean trypsin inhibitor (pH 7.4 at 25°C) with a Kinematica Polytron. The homogenates were centrifuged at 47,800 g for 10 min. Pellets were resuspended in 10 volumes of binding assay buffer (20 mM Hepes, 1 mM EGTA, 5 mM MgCl<sub>2</sub>, 150 mM NaCl, bacitracin 0.25 mg/ml, soya bean trypsin inhibitor 0.1 mg/ml, and bovine serum albumin 2 mg/ml, pH 6.5 at 25°C) using a teflon homogenizer, 15 strokes at 500 rpm. The homogenate was further diluted in binding assay buffer to give a final concentration of 0.5 mg original wet weight/1 ml buffer. For the binding assay, 50 µl of buffer (for total binding) or unlabeled CCK-8 sulfated to give a final concentration of 1 µM (for nonspecific binding) or the compounds of Formula I (for determination of inhibition of <sup>125</sup>I-CCK binding) and 50 µl of 500 pM <sup>125</sup>I-CCK-8 (i.e. 50 pM final concentration) were added to 400 µl of the membrane suspensions in microfuge tubes. All assays were run in duplicate. The reaction mixtures were incubated at 25°C for 2 hours and the reaction terminated by rapid filtration (Brandell 24 well cell harvester) over Whatman GF/C

filters, washing 3 x 4 mls with ice-cold 100 mM NaCl. The radioactivity on the filters was counted with a LKB gamma counter.

## 2. CCK Receptor Binding (Brain)

5

CCK-8 sulphated was radiolabelled and the binding was performed according to the description for the pancreas method with minor modifications.

10

Male Hartley guinea pigs (300-500g) were sacrificed by decapitation and the cortex was removed and homogenized in 25 mL ice-cold 0.32 M sucrose. The homogenates were centrifuged at 1000 g for 10 minutes and the resulting supernatant was re-centrifuged at 20,000 g for 20 minutes. The P<sub>2</sub> pellet was resuspended in binding assay buffer (20 mM N-2-hydroxyethyl-piperazine-N'-2-ethane sulfonic acid (HEPES), 5 mM MgCl<sub>2</sub>, 0.25 mg/ml bacitracin, 1 mM ethylene glycol-bis-(β-aminoethyl-ether-N,N'-tetraacetic acid) (EGTA)pH 6.5 at 25°C, using a teflon homogenizer (5 strokes at 500 rpm) to give a final concentration of 10 mg original wet weight 11.2 mls buffer. For the binding assay, 50μl of buffer (for total binding) or unlabeled CCK-8 sulfate to give a final concentration of 1μM (for nonspecific binding) or the compounds of Formula I (for determination of inhibition of <sup>125</sup>I-CCK-8 binding) and 50 μl of 500 pM <sup>125</sup>I-CCK-8 (i.e. final concentration of 50 pM) were added to 400 μl of the membrane suspensions in microfuge tubes. All assays were run in duplicate. The reaction mixtures were incubated at 25°C for 2 hours and then the reaction was terminated on Whatman GF/C filters by rapid filtration (Brandell 24 well cell Harvester) with 3 x 5 ml washes of cold 100 mM NaCl. The radioactivity on the filters was then counted with a LKB gamma counter.

20

## 5. Gastrin Antagonism

25

Gastrin antagonist activity of compounds of Formula I is determined using the following assay.

25

### A. Gastrin Receptor Binding in Guinea Pig Gastric Glands

#### Preparation of guinea pig gastric mucosal glands

30

Guinea pig gastric mucosal glands were prepared by the procedure of Chang et al., Science 230, 177-179 (1985) with slight modification. Gastric mucosa from guinea pigs (300-500 g body weight, male Hartley) were isolated by scraping with a glass slide after washing stomachs in ice-cold, aerated buffer consisting of the following: 130 mM NaCl, 12 mM NaHCO<sub>3</sub>, 3 mM NaH<sub>2</sub>PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO<sub>4</sub>, 3 mM K<sub>2</sub>HPO<sub>4</sub>, 2 mM MgSO<sub>4</sub>, 1 mM CaCl<sub>2</sub>, 5 mM glucose and 4 mM L-glutamine, 50 mM HEPES, 0.25 mg/ml bacitracin, 0.10 mg/ml soya bean trypsin inhibitor, 0.1 mg/ml bovine serum albumin, at pH 6.5, and then incubated in a 37°C shaking water bath for 40 minutes in buffer containing 1 mg/ml collagenase and bubbled with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. The tissues were passed twice through a 5 ml syringe to liberate the gastric glands, and then filtered through Nitex #202 gauge nylon mesh. The filtered glands were centrifuged at 272 g for 5 minutes and washed twice by resuspension in 25 ml buffer and centrifugation.

40

#### B. Binding studies

45

The washed guinea pig gastric glands prepared as above were resuspended in 25 ml of standard buffer. For binding studies, to 250 μl of gastric glands, 30 μl of buffer (for total binding) or gastrin (3 μM final concentration, for nonspecific binding) or test compound and 20 μl of <sup>125</sup>I-gastrin (NEN, 2200 Ci/mmol, 0.1 nM final concentration) were added. AV assays were run in triplicate. The tubes were aerated with 95% O<sub>2</sub> and 5% CO<sub>2</sub> and capped. The reaction mixtures after incubation at 25°C for 30 minutes in a shaking water bath were rapidly filtered (Brandell 24 well cell harvester) over Whatman and G/F B filters presoaked in assay buffer and immediately washed further with 3 x 4 ml of 100 mM ice cold NaCl. The radioactivity on the filters was measured using a LKB gamma counter.

## In Vitro Results

### Effect of The Compounds of Formula I on <sup>125</sup>I-CCK-8 receptor binding

55

The preferred compounds of Formula I are those which produced dose-dependent inhibition of specific <sup>125</sup>I-CCK-8 binding as defined as the difference between total and non-specific (i.e. in the presence of 1 μM CCK) binding.

Drug displacement studies were performed with at least 10 concentrations of compounds of formula 1 and the IC<sub>50</sub> values were determined by regression analysis. IC<sub>50</sub> refers to the concentration of the compound required to inhibit 50% of specific binding of <sup>125</sup>I-CCK-8.

The data in Table I were obtained for compounds of Formula 1.

5

TABLE I

10

## CCK RECEPTOR BINDING RESULTS

IC<sub>50</sub> (μM)

15

20

25

<u>Compound</u> <u>of Ex #</u>	<u>125I-CCK</u> <u>Pancreas</u>	<u>25I-CCK</u> <u>Brain</u>	<u>25I-Gastrin</u> <u>Gastric Glands</u>
1	> 3	3.68	N.D.
2	> 3	0.51	N.D.

N.D. = NO DATA

EXAMPLES

30 Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species and conditions are intended to be further illustrative of the invention and not limitative of the reasonable scope thereof.

35

Synthesis of N-[1,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-carboxyethyl-N'-{[3-methylphenyl]-urea}.

40

A. N-[1,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-methylcarboxyethyl-N'-{[3-methylphenyl]-urea}.

45

To a solution of 1,3-dihydro-3(R,S)-amino-5-phenyl-2H-1,4-benzodiazepin-2-one (100 mg, 0.377 mmole) in 2 ml of toluene was added 56 mg (0.189 mmole) triphosgene and 56 μL of triethylamine (0.377 mmole). After 10 minutes, 100 mg (0.517 mmole) of N-methoxycarbonylethyl-m-toluidine and triethylamine (56 μL, 0.377 mmole) were added and stirring was continued for 2 additional hours. The reaction mixture was concentrated to dryness. Ethyl acetate and water were added to the residue. The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic extracts were dried (sodium sulfate) and concentrated to give approximately 150 mg of crude product. Preparative thick layer chromatography on 0.5 mm x 20 cm x 20 cm precoated silica gel plates (ethyl acetate-hexane, 1:1 v/v elution) afforded 60 mg of the analytical product after it was crystallized from petroleum ether: m.p. 197-198°C.

HPLC = 99.3% pure at 214 nm; TLC R<sub>f</sub> = 0.30 (EtOAc-hexane, 1:1).

NMR (DMSO-D<sub>6</sub>): Consistent with structure assignment and confirms presence of solvent.

FAB MS: 485 (M<sup>+</sup> + 1).

Analysis for C<sub>28</sub>H<sub>28</sub>N<sub>4</sub>O<sub>4</sub>:

55

Calculated: C, 69.40, H, 5.82, N, 11.56

Found: C, 69.19, H, 5.96, N, 11.52

B. N-[1,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-carboxyethyl-N'-(3-methylphenyl)-urea).

5      N-[1,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-methylcarboxyethyl-N'-(3-methylphenyl)-urea), (40 mg) was mixed with 7 mg of lithium hydroxide in 2 ml of dimethoxyethane and 0.5 ml of water. The reaction mixture was stirred for 8 hours and concentrated in vacuo. Ethyl acetate was added to the residue and 1 N HCl solution was added until the mixture was neutral. The ethyl acetate extracts were dried (sodium sulfate) and concentrated to give 30 mg of crude product. The crude product was triturated with ethyl acetate and petroleum ether to give the title compound: m.p. >175°C (d).  
10     HPLC = 95% pure at 214 nm; TLC R<sub>f</sub> = 0.45 (EtOAc).  
20     NMR (DMSO-D<sub>6</sub>): Consistent with structure assignment and confirms presence of solvent. FAB MS: 471 (M<sup>+</sup> + 1).  
Analysis for C<sub>27</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>•0.35 EtOAc•0.15 H<sub>2</sub>O:  
Calculated:    C, 67.67, H, 5.82, N, 11.12  
15     Found:        C, 67.70, H, 5.97, N, 11.14

#### EXAMPLE 2

20     Synthesis of N-[1,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N-carboxyethyl-N'-(3-methylphenyl)-urea}.

A. 1,3-Dihydro-1-methyl-3(R,S)-(methylcarboxyethyl)amino-5-phenyl-1H-1,4-benzodiazepin-2-one.

25     1,3-Dihydro-1-methyl-3(R,S)-amino-5-phenyl-2H-1,4-benzodiazepin-2-one (1 g, 377 mmole) was dissolved in 10 ml of dry N,N-dimethylformamide and treated with 1.04 g of solid sodium carbonate at room temperature. To this suspension was added 810 mg (3.77 mmole) of methyl 3-iodopropionate and the reaction mixture was stirred overnight. An additional 800 mg of methyl 3-iodopropionate and 500 mg of sodium carbonate were added and the reaction mixture was then heated to 50°C. After 24 hours the reaction mixture was filtered and concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic phase was washed twice more with water, then dried (sodium sulfate), and concentrated to yield 720 mg of crude product. The title compound was obtained as an oil which crystallized on standing after flash silica gel chromatography employing ethyl acetate-hexane (1:1 v/v). Recrystallization from ether afforded the analytical material which had m.p. 136-137°C.

35     B. N-[1,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N-methylcarboxyethyl-N'-(3-methylphenyl)-urea).

40     To a solution of 130 mg (0.37 mmole) of 1,3-dihydro-1-methyl-3(R,S)-(methylcarboxyethyl)amino-5-phenyl-1H-1,4-benzodiazepin-2-one in 2 ml of tetrahydrofuran was added 48 µL of m-toluidine isocyanate at room temperature. The resulting solution was protected from moisture and stirred for 1 hour. The solvent was removed under reduced pressure and the residual solid was recrystallized from a methanol-ethyl acetate-hexane solvent mixture to give 110 mg of the title compound with m.p. 198°C.

45     C. N-[1,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N-carboxyethyl-N'-(3-methylphenyl)-urea).

50     N-[1,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N-methylcarboxyethyl-N'-(3-methylphenyl)-urea (70 mg) was mixed with 25 mg of lithium hydroxide in 3 ml of dimethoxyethane and 0.5 ml of water. The reaction mixture was stirred for 4 hours and concentrated in vacuo. Ethyl acetate and water were added to the residue and the resulting mixture was neutralized with 1N HCl solution. The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic extracts were dried (sodium sulfate) and concentrated to give the crude product. The crude product was recrystallized from a methanol-ethyl acetate-hexane solvent mixture to give the title compound: m.p. 172-174°C (d).  
HPLC = 99.4% pure at 214 nm; TLC R<sub>f</sub> = 0.48 (EtOAc).

55     NMR (DMSO-D<sub>6</sub>): Consistent with structure assignment and confirms presence of solvent.

FAB MS: 471 (M<sup>+</sup> + 1).

Analysis for C<sub>27</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>•0.40 EtOAc•0.20 H<sub>2</sub>O:


Calculated:    C, 67.43, H, 5.86, N, 11.00.

Found: C, 67.44, H, 5.48, N, 10.98.

**Claims**

5

1. A compound of Formula I:




wherein:

R<sup>1</sup> is H, -(CH<sub>2</sub>)<sub>2</sub>-CO<sub>2</sub>CH<sub>3</sub> or -(CH<sub>2</sub>)<sub>2</sub>-CO<sub>2</sub>H;

25

30




35

R<sup>3</sup> is absent, one or two of Halogen or CH<sub>3</sub>;

R<sup>4</sup> is absent, one or two of Halogen or CH<sub>3</sub>;

R<sup>5</sup> is

40



or the optical isomers, prodrugs or pharmaceutically acceptable salts thereof.

45

2. The compound of Claim 1, in which the compound is N-{1,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl}-N'-carboxyethyl-N'-(3-methylphenyl)-urea or N-{1,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl}-N-carboxyethyl-N'-(3-methylphenyl)-urea or a pharmaceutically acceptable salt thereof.

50

3. A pharmaceutical composition having cholecystokinin antagonist activity, comprising a pharmaceutical carrier and dispersed therein a therapeutically effective but non-toxic quantity of the compound of Claim 1 or claim 2.

55

4. The use of a compound of claim 1 or claim 2 for the manufacture of a medicament for producing cholecystokinin antagonist activity in a mammal.

5. The use of a compound of claim 1 or claim 2 for the manufacture of a medicament for treating anxiety disorders in a mammal.

6. The use of a compound of claim 1 or claim 2 for the manufacture of a medicament for treating panic disorders in a mammal.
7. The use of a compound of claim 1 or claim 2 for the manufacture of a medicament for treating gastrointestinal diseases in a mammal.  
5
8. The use of a compound of claim 1 or claim 2 for the manufacture of a medicament for treating central nervous system disorders in a mammal.
9. The use of a compound of claim 1 or claim 2 for the manufacture of a medicament for treating oncologic disorders in a mammal.  
10
10. The use of a compound of claim 1 or claim 2 for the manufacture of a medicament for preventing or treating the withdrawal response produced by chronic treatment or abuse of drugs or alcohol in a mammal.
11. The use of a compound of claim 1 or claim 2 for the manufacture of a medicament for inducing miosis following intraocular examinations or surgery in a mammal.  
15
12. The use of a compound of claim 1 or claim 2 for the manufacture of a medicament for inducing analgesia in a mammal.
13. The use of a compound of claim 1 or claim 2 for the manufacture of a medicament for preventing or treating neurodegenerative disorders in a mammal.  
20

25

30

35

40

45

50

55

European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number

EP 92 30 3193

## DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
D, X	JOURNAL OF MEDICINAL CHEMISTRY vol. 32, no. 1, January 1989, WASHINGTON US pages 13 - 16; M.G. BOCK ET AL.: 'Benzodiazepine Gastrin and Brain Cholecystokinin Receptor Ligands: L-365,260' * the whole article, particularly page 15, table I, compounds 9-14 * ---	1-13	C07D243/24 A61K31/55
D, P, X	EP-A-0 434 364 (MERCK & CO. INC.)  * the whole application, particularly examples 5, 11 and 26 *  -----	1-13	
The present search report has been drawn up for all claims			
Place of search	Date of compilation of the search	Examiner	
THE HAGUE	07 JULY 1992	ALLARD M. S.	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons -----           & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			